tbuckley/cabot-search huggingface dataset:
The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer
Authors: Najwa El Kadi, Luo Wang, April Davis, Hasan Korkaya, Alexander Cooke, Varun Vadnala, Noah A. Brown, Bryan L. Betz, Marilia Cascalho, Gregory P. Kalemkerian, Khaled A. Hassan
Journal: Cancer Research (2018)

: Almost all patients with EGFR-driven lung cancer who are treated with EGFR tyrosine kinase inhibitors (TKI) develop resistance to treatment. A single base (c.2369C>T) transition mutation, EGFR T790M, is the most frequent resistance event after first-generation exposure to EGFR TKIs. Whether T790M mutation is acquired or is selected from a preexisting clone has been a matter of significant debate. In this study, we show that treatment with EGFR TKIs leads to activation of the NFκB pathway, which in turn induces expression of activation-induced cytidine deaminase (AICDA). In turn, AICDA causes deamination of 5-methylcytosine to thymine at position c.2369 to generate the T790M mutation. Pharmacologic inhibition of the NFκB pathway or knockout of AICDA decreased the frequency or prevented the development of T790M mutation, respectively. In addition, patients treated with first-line EGFR TKI displayed increased expression of AICDA and detection of the T790M mutation upon progression. These results identify the mechanism of T790M acquisition and present an opportunity to target the process to delay or prevent it. SIGNIFICANCE: These findings identify the mechanism behind acquisition of a common resistance mutation to TKI treatment in lung cancer.
Anti-mutagenic activity of Methyl Sulfonyl Methane (MSM) in ICR mice
Authors: Janei Huan, Jacob Nowicki, Lin Peng, Gray Anderson, Diane Nowicki, Mian-Ying Wang
Journal: Cancer Research (2006)

4814  Inhibiting mutagenicity in experimental animals can provide an end point to evaluate the anti-mutagenic activity and safety of chemopreventive agents, and to predict their protective efficacy in humans. In this study, we studied the inhibitory ability of Methyl Sulfonyl Methane (MSM) on micronuclei (MN) formation of erythrocytes (ETCs) in bone marrow, induced by cyclophosphamide (CPA), a well-known anticancer drug that is mutagenic. MSM is a nutritional supplement used for pain relief. It is naturally found in food and in the human body. Our previous study has demonstrated that MSM possesses a cancer preventive activity in DMBA-induced mammary gland tumors of female SD rats. In this study, the inhibitory effect of MSM on MN formation induced by CPA was analyzed. Thirty 22-24g ICR mice were divided into 5 groups: control, 6.25, 12.5, 25, and 50 mg of CPA, 3 males and 3 females in each group. The control group was given 0.1ml/10 g body weight of saline by i.p. The other groups were given 6.25, 12.5, 25, and 50 mg/kg of CPA in saline by i.p. All animals were sacrificed by cervical dislocation at the 24th hour after CPA administration. The frequency of MN in bone marrow erythrocytes was determined under the light microscope (LM) at 1000X. The frequency of MN was 0.85 in the control group, 5.8, 9.4, 15.3, and 28.5 per 1000 ETC corresponding to the four doses of CPA respectively. The result indicated that 25 mg/kg CPA provided the optimum level of mutagenicity, which was chosen to be used for next experiment. Thirty 22-24 g ICR mice were divided into 5 groups: 2 untreated controls, and 3%, 5%, and 8% MSM groups. Each group contained 3 males and 3 females. MSM was supplied for 1 week in drinking water. On the 7th day, 25 mg/kg CPA was given by i.p. to all animals except the negative control group. All animals were sacrificed by cervical dislocation at the 24th hour after CPA administration. The frequency of MN was assessed under LM. MN in the negative control, positive CPA control, and 3%, 5%, and 8% MSM group were 0.85±1.03, 15.3±6.6, and 4.2±1.9, 4.6±1.5, and 2.3±1.5 per 1000 ETCs, respectively. The data indicated in an extremely significant manner that there was a 73%, 70%, and 85% inhibition of MN formation in the three doses of MSM compared to that of the positive controls. In conclusion, MSM is able to inhibit MN formation in bone marrow erythrocytes of ICR mice. Therefore, MSM may strongly protect the bone marrow from the toxicity of anticancer drugs and is safe for long-term preventive purposes. This data provides evidence, for the first time, of in vivo anti-mutagenicity of MSM on mammalian cells.
Infographic. Mechanisms of acute adductor longus injuries in male football players
Authors: Andreas Serner, Andrea Britt Mosler, Johannes L Tol, Roald Bahr, Adam Weir
Journal: British Journal of Sports Medicine (2018)

Acute muscle injuries are common in football, however, our understanding of how they occur is very limited. Most clinicians will have limited information about injury mechanisms, which is usually extrapolated from clinical history taking. Even …
Abstract 12265: The Improvement of Hypoxia Correlates with Neuroanatomical and Developmental Outcomes in Infants with Transposition of the Great Arteries or Single Ventricle Physiology
Authors: Keijiro Ibuki, Kazuhiro Watanabe, Naoki Yoshimura, Tachiyo Kakimoto, Mie Matsui, Kazuyoshi Saito, Sayaka Ozawa, Keiichi Hirono, Taketoshi Yoshida, Kyo Noguchi, Fukiko Ichida
Journal: Circulation (2011)

OBJECTIVES: We performed a prospective longitudinal study of the neuroanatomical and developmental changes in infants with transposition of the great arteries (TGA) or single ventricle (SV) physiology, to identify variables in anatomical development of the brain associated with functional impairment. We hypothesized that infants with TGA, whose oxygenation improved after early surgical correction, would have better neuroanatomical and developmental outcome than those with SV physiology who continued to have hypoxia. METHODS: Thirty-three infants with congenital heart defects, 23 with SV and 10 with TGA, were studied at around one year old (time 1) and three years old (time 2) by magnetic resonance imaging of the brain. Neurodevelomental assessment was performed at the same time. RESULTS: The whole and frontal lobe volumes were significantly reduced in both groups at time 1 compared with normal controls (P<0.01). However, by time 2 whole and frontal brain volumes were normal in the TGA group, but remained ...
Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials
Authors: M. Mau-Sorensen, M. van Bussel, M. Kuipers, D.L. Nielsen, H.M. Verheul, P. Aftimos, M.J.A. de Jonge, B. van Triest, J. Falkenius, J. Debus, E. Troost, M. Samuels, B. Sarholz, V. Budach, S. Goel, G. Locatelli, P.F. Geertsen
Journal: Annals of Oncology (2018)
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
Authors: Uwe Reuter, Peter J Goadsby, Michel Lanteri-Minet, Shihua Wen, Peggy Hours-Zesiger, Michel D Ferrari, Jan Klatt
Journal: The Lancet (2018)
Feasibility and value of incorporating pharmacogenomic testing for genetic variants in <i>UGT1A1</i> and <i>DPYD</i> genes in patients receiving irinotecan and/or 5-fluorouracil chemotherapy.
Authors: Candice Baldeo, Caren Hughes, Pashtoon Murtaza Kasi
Journal: Journal of Clinical Oncology (2018)

814 Background: The importance of pharmacogenomics in optimizing drug doses and avoiding adverse events is increasingly being recognized. The FDA has listed pharmacogenomic biomarkers as part of drug labeling in many medications including chemotherapies such as 5-fluorouracil and irinotecan. Pharmacogenomics may enable selection of the most tolerable treatment without compromising treatment success. Variation in the dihydropyrimidine dehydrogenase ( DPYD) and UGT1A1 gene mutations can increase the risk of 5-FU and irinotecan based chemotherapy respectively. Also, the feasibility of testing in real-time and incorporating results into management has not been demonstrated. The focus of our study was to demonstrate this in the real world scenario as a quality improvement project. Methods: In July-August 2017, 89 patients who were on irinotecan and/or 5-FU chemotherapy were tested for DPYD and UGT1A1 genetic variations at Mayo Clinic Florida. Testing was done through blood sample which was collected at routine clinic visit prior to starting therapy or in patients already receiving chemotherapy. Pharmacy electronic consultation was obtained for recommendations regarding current and/or future chemotherapy regimens, based on pharmacogenomics results. A medication therapy management (MTM) consultation from the pharmacist was incorporated and included into the patient’s chart. Results: Total number of patients who has some variation in the UGT1A1 and/or DPYD gene was 60 (67%). Specifically, there were 12 patients who were homozygous for the UGT1A1 gene and 3 homozygous for DPYD gene. Both genes were affected in 3 patients. One patient was triple heterozygous for DPYD and homozygous for UGT1A1. Pharmacogenomic results were obtained for these patients within 5 business days. Conclusions: A higher prevalence of UGT1A1 and DPYD variants were reported in our patient cohort tested than what is reported in the literature. Additionally, we were able to obtain results for these patients in a timely fashion. This was then further incorporated into medication therapy management consultation from the pharmacist, which added further value.
Should I Participate in a Cardiac Rehabilitation Program?
Authors: Tamara B. Horwich, Gregg C. Fonarow
Journal: JAMA Cardiology (2018)

Cardiac rehabilitation (CR) is a multidisciplinary, medically supervised, outpatient program that aims to optimize physical, mental, and social functioning of people with cardiovascular disease.These programs are designed with the goal of halting or reversing the progression of cardiovascular disease and improving outcomes.Aerobic exercise training in aclassicgymisgenerallyconsideredthecornerstoneofCRandisofminimal risk in patients with cardiovascular disease.Other key components of CR include nutrition counseling, psychological support, stress management, tobacco cessation, and education on topics relevant to cardiovascular disease such as blood pressure, diabetes, and cholesterol management.Cardiac rehabilitation is usually based at a hospital or physicians' office and traditionally consists of 2 to 3 one-hour sessions per week for 12 to 18 weeks for a total of at least 36 hours.Intensive CR programs provide a more rigorous experience in nutrition counselling, stress management practice, and group support in addition to exercise training and may require up to 72 hours of participation.
Barbara Mary Katić
Authors: Christina Katić, Catriona Barr
Journal: BMJ (2018)

Barbara Mary Katic (nee Cooke) was born into a medical family—her grandfather, father, and uncle were all doctors—and became the first woman in her family to practise medicine. Her grandfather’s and father’s practice was based in the family home, Ashfield House, in Aspull, Wigan. Her mother worked as the practice manager.

As a child, Barbara experienced the anxiety and stress of the war years. She then made a choice between her two passions, ballet and medicine, opting for medicine. After qualifying from Trinity College Dublin in 1953, she returned to finish training at Wigan Infirmary, and then joined the family GP practice, now run by her brother, Peter Cooke.

In 1956 Barbara followed her adventurous streak and secured a work …
Time for a new obesity narrative
Authors: Johanna Ralston, Hannah Brinsden, Kent Buse, Vanessa Candeias, Ian Caterson, Trevor Hassell, Shiriki Kumanyika, Patricia Nece, Sania Nishtar, Ian Patton, Joseph Proietto, Ximena Ramos Salas, Srinath Reddy, Donna Ryan, Arya M Sharma, Boyd Swinburn, John Wilding, Euan Woodward
Journal: The Lancet (2018)
Abstract 12827: Mouse Model of LEOPARD Syndrome Reveals a Dominant Negative Function of the PTPN11 (Shp2) Mutation and a Mechanism of Regulation and Therapy for Hypertrophic Cardiomyopathy
Authors: Talita Marin, Kimberly Keith, Prajna Guha, Benjamin Davies, Clare Malone, David Conner, Xue Wu, Michael Bauer, Bonnie Wang, Roderick Bronson, Kleber Franchini, Benjamin Neel, Maria Kontaridis
Journal: Circulation (2010)

Over 90% of cases of LEOPARD syndrome (LS), a rare autosomal dominant multi-systemic disease, are caused by mutations in the protein tyrosine phosphatase non-receptor type 11 gene ( PTPN11 ), which encodes Shp2. However,  in vivo  mechanisms and signlaling pathways that regulate LS in the heart remain undefined. We hypothesize that LS mutations in the heart behave as dominant negatives and aberrantly activate downstream signaling pathways to cause hypertrophic cardiomyopathy (HCM). To test this, we generated inducible knock-in mice to one of the most common Shp2 mutations in LS, Y279C. Inducible mice were crossed to EIIA-whole body deleter Cre mice to generate LS/+ mice. Viable and born at Mendelian ratios, LS/+ mice recapitulate the human disease phenotype, with abnormal facies, growth-retardation, and abnormal chest walls. Echocardiography and histopathology reveal LS/+ mice to have progressive left ventricular HCM peaking at 12-16 weeks, followed by dilation and decreased ejection fraction by 20 weeks, as compared to wildtype littermates (WT). The cardiac fetal gene program is also reactivated in LS/+, further validating the HCM observed in these mice. Biochemically, LS/+ hearts have significantly reduced Shp2 phosphatase activity  in vivo . While no significant change in basal Erk/MAPK activity is observed, upon insulin stimulation, lysates from LS/+ hearts have significantly reduced Erk/MAPK response, as compared to WT. In parallel, the Akt/TSC2/S6K pathway and the cardiac stress-mediated signaling pathways (pStat3, p38 and JNK) are all significantly elevated, with concomitant increase in nuclear NFAT. To determine whether PI3K/Akt signaling facilitates the hypertrophic response in LS, we isolated LS/+ and WT primary MEFs; LS/+ MEFs were significantly larger in size and shape than WT and, importantly, overnight treatment of the LS/+ cells with the Akt/mTOR pathway inhibitor, rapamycin, reversed the hypertrophic phenotype. Indeed,  in vivo,  mice given a daily low-dose of rapamycin for a period of four weeks have significantly improved cardiac function, with reversal of the HCM, as observed by echocardiography. Taken together, these data reveal the first  in vivo  analysis for LS and identify rapamycin as a targetable therapy for HCM in LS patients.
A Case of Tophaceous Pseudogout on 18F-FDG PET/CT Imaging
Authors: Guohua Shen, Minggang Su, Bin Liu, Anren Kuang
Journal: Clinical Nuclear Medicine (2018)

A 53-year-old man with a 10-year history of gout was admitted to our hospital due to chronic low back pain. Initial CT examinations showed a high-density mass with bone destruction of bilateral facet joints at the L3 to L5 level. MRI findings also revealed lesion with the dural sac compression. On PET/CT, the juxta-articular mass of bilateral L3 to L5 facet joints showed abnormal FDG uptake with an SUVmax of 4.2. The possible diagnosis may be gouty tophi; however, the biopsy revealed the diagnosis of calcium pyrophosphate dihydrate deposition disease, also referred to as pseudogout.
Abstract 14101: Risk of Cardiovascular Disease Morbidity & Mortality in the Population During Major Football Games: A Systematic Review and Meta-analysis of Observational Studies
Authors: Lan Guo, Qingshan Geng, Huan Ma
Journal: Circulation (2017)

Introduction: Whether there has been or not increased hospitalizations and/or deaths due to cardiovascular disease during major football tournament(MFT) remains controversial. Methods: Relevant stu...
Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer
Authors: Xuxu Sun, Sam C. Wang, Yonglong Wei, Xin Luo, Yuemeng Jia, Lin Li, Purva Gopal, Min Zhu, Ibrahim Nassour, Jen-Chieh Chuang, Thomas Maples, Cemre Celen, Liem H. Nguyen, Linwei Wu, Shunjun Fu, Weiping Li, Lijian Hui, Feng Tian, Yuan Ji, Shuyuan Zhang, Mahsa Sorouri, Tae Hyun Hwang, Lynda Letzig, Laura James, Zixi Wang, Adam C. Yopp, Amit G. Singal, Hao Zhu
Journal: Cancer Cell (2018)
Statins at Dialysis Transition—Supportive but Not Sufficient
Authors: Daniel Edmonston, Myles Wolf, Michael Pencina
Journal: JAMA Network Open (2018)

Elani Streja, MPH, PhD; Elvira O. Gosmanova, MD; Miklos Z. Molnar, MD, PhD; Melissa Soohoo, MPH; Hamid Moradi, MD; Praveen K. Potukuchi, MS; Kamyar Kalantar-Zadeh, MD, MPH, PhD; Csaba P. Kovesdy, MD
Cytomorphological Analysis of Thyroid Nodules Diagnosed as Follicular Variant of Papillary Thyroid Carcinoma: a Fine Needle Aspiration Study of Diagnostic Clues in 42 Cases and the Impact of Using Bethesda System in Reporting—an Institutional Experience
Authors: Levent Trabzonlu, Nadir Paksoy
Journal: Endocrine Pathology (2018)
P3.09-07 Immunohistochemical Expression of Programmed Death-Ligand 1 in Diabetic Patients vs Non-Diabetics with Non-Small Cell Lung Cancer
Authors: M. Zaleski, S. Sharzehi, R. Voland, J. Varlotto, N. Rassaei, Y. Liu
Journal: Journal of Thoracic Oncology (2018)
Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017
Authors: J.-Y. Blay, M. Toulmonde, N. Penel, O. Mir, C.M. Chevreau, P. Anract, E. Bompas, M. Rios, N. Firmin, A. Italiano, S. Piperno-Neumann, J.-E. Kurtz, F. Duffaud, P. Rosset, F. Bertucci, C. Perrin, C. Chemin, F. Ducimetiere, F. Gouin, A. Le Cesne
Journal: Annals of Oncology (2018)
Medical services at the 2017 Sapporo Asian winter games: injury and illness epidemiology at a 34-nation multisport event
Authors: Kota Watanabe, Takao Akama, Shin Asakawa, Kimitaka Fukuda, Hiroya Sakai, Toru Okuwaki, Tomohito Imai, Hiroko Sato, Masaki Katayose, Manikavasagam Jegathesan, Nadia Al Shamali
Journal: British Journal of Sports Medicine (2018)

We describe the medical services provided and report the injuries and illnesses that occurred at the eighth Asian Winter Games 2017.A total of 2010 athletes and team officials from 32 National Olympic Committees and 2 guest countries attended this event; medical services were provided for 16 days. Medical data (medical care and physiotherapy) were collected for the same period by the organising committee for athletes and non-athletes (team officials, workforce, media and spectators) and recorded on the electronic medical record system at the medical rooms in the venues and the team residences.We recorded 745 medical encounters (medical care, 443; physiotherapy, 302), of which 549 (74%) were among athletes. There were 214 injuries as well as 144 illnesses and other medical conditions. Of the 1164 athletes, 549 (47%) utilised the services. Ice hockey, snowboarding and alpine skiing had high rate of medical encounters. More than half of the delegations were not accompanied by team doctor, and rate of medical encounters was high in these teams. The vast majority of patients transferred to hospital for further care were mostly athletes (n=36 out of 41), mostly alpine skiers and ice hockey players.Injuries and illnesses varied depending on NOC medical staffing and sport events. These data will serve organisers of medical and physiotherapy services in the Asian Winter Games and similar large events.
P2.15-10 Determinants of Health Utility Scores (HUS) in Patients with ALK Rearranged Non-Small Cell Lung Cancer.
Authors: B. Id Said, K. Hueniken, M.C. Brown, D. Patel, M. Liang, C. Labbe, L. Eng, H. Naik, P. Bradbury, F. Shepherd, N. Leighl, G. Liu, G. O'Kane
Journal: Journal of Thoracic Oncology (2018)
Patient reported outcomes after the treatment of early stage non-small cell lung cancer by stereotactic body radiotherapy compared to surgery
Authors: L. Alberts, H.B. Wolff, E.A. Kastelijn, F.J. Lagerwaard, S. Senan, S.Y. El Sharouni, F.M.N.H. Schramel, V.M.H. Coupe
Journal: Annals of Oncology (2018)
Dual cholinergic signals regulate daily migration of hematopoietic stem cells and leukocytes
Authors: Andrés García-García, Claudia Korn, María García-Fernández, Olivia Domingues, Javier Villadiego, Daniel Martín-Pérez, Joan Isern, José A. Bejarano-García, Jacques Zimmer, José A. Pérez-Simón, Juan J. Toledo-Aral, Tatiana Michel, Matti S. Airaksinen, Simón Méndez-Ferrer
Journal: Blood (2018)
P2.12-01 Efficacy of Belotecan as Second-Line Treatment for Recurrent Small Cell Lung Cancer: A Phase IIb Randomized Multicenter Study
Authors: J. Kang, K.H. Lee, D. Kim, S. Kim, H.R. Kim, J. Kim, J.H. Choi, H.J. An, J. Kim, J.S. Jang, B. Kim, H.T. Kim
Journal: Journal of Thoracic Oncology (2018)
MA02.03 ASTRIS: A Real World Treatment Study of Osimertinib in Patients with EGFR T790M-Positive NSCLC
Authors: Y. Wu, B.C. Cho, Q. Zhou, G. Chang, L. Jiang, G. Metro, C. Martin, G. De Castro, J. Vansteenkiste, D. Vicente, A. Milner, J. Rigas, Y. Chen, M. Provencio
Journal: Journal of Thoracic Oncology (2018)
Public awareness of cancer in the Gaza-Strip: A cross-sectional study
Authors: M.S. Elshami, M. Alkhatib, A. Elshami, K. Abu-Nemer, A. Qandeel, M. Hana, N. Alshorbassi, G. Matar, O. Baraka, M. Elblbessy, L. Albarqouni, B. Bottcher
Journal: Annals of Oncology (2018)
Need for a stratified analysis in stage I malignant ovarian germ cell tumors (MOGCT): Prospective survival analysis of cases collection from the French rare malignant ovarian tumors (TMRO) network &amp; GINECO group
Authors: T. de la Motte Rouge, F. Derquin, A. Floquet, J. Edeline, J.-P. Lotz, J. Alexandre, P. Pautier, G. Ferron, E. Boissier, C. Lefeuvre-Plesse, H. Vegas, A. Patsouris, E. Kalbacher, D. Berton-Rigaud, A.-C. Hardy Bessard, V. Lavoué, I.L. Ray-Coquard
Journal: Annals of Oncology (2018)
Prognostic associations of early prostate-specific antigen (PSA) changes in patients with metastatic castration-resistant prostate cancer treated with with abiraterone acetate or enzalutamide
Authors: F. López Campos, I. Moreno, A. Conde-Moreno, A. Gómez-Iturriaga, M. Ruiz Vico, N. Romero Laorden, I. Henríquez López, P. Peleteiro Higuero, R. Lozano Mejorada, T. Piquer, M. Couselo, J. Gómez Ramos, J. Navarro, P. Barrionuevo Castillo, R. García, R. Villatoro, A. Montesa, M.I. Saez, B. Herrera, E. Castro Marcos
Journal: Annals of Oncology (2018)
Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation
Authors: Inès Mottas, Ahmet Bekdemir, Alessandra Cereghetti, Lorenzo Spagnuolo, Yu-Sang Sabrina Yang, Marie Müller, Darrell J. Irvine, Francesco Stellacci, Carole Bourquin
Journal: Biomaterials (2018)
Angiotensin converting enzyme inhibitors and lung cancer
Authors: Deirdre Cronin-Fenton
Journal: BMJ (2018)

Any extra risk must be balanced against the mortality benefits of ACEI use

Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers are indicated for the treatment of hypertension, heart disease, renal insufficiency, and chronic kidney disease. ACEIs decrease the production of angiotensin II, whereas angiotensin receptor blockers selectively block its binding to angiotensin receptors.1 These drugs target the renin angiotensin aldosterone system, which may play a role in cancer development.23

In a linked paper , Hicks and colleagues (doi:10.1136/bmj.k4209) use registry data from the UK Clinical Practice Research Datalink (CPRD) to investigate the association of antihypertensive drugs with the risk of lung cancer.4 Their study population included 992 061 people, newly treated with antihypertensive drugs between 1995 and 2015, with follow-up until end of December 2016. Their findings indicate an increased risk of lung cancer associated with the use of ACEIs compared with angiotensin receptor blockers; with the highest risk associated with more than 10 years of ACEI use. The authors propose …
The clinical impact of targeted next generation sequencing (tNGS) in the treatment of metastatic prostate cancer
Authors: P.M.C. Coelho Barata, P. Mendiratta, M. Sadaps, S. Klek, M. Ornstein, T. Gilligan, P. Grivas, B.I. Rini, D. Sohal, J.A. Garcia
Journal: Annals of Oncology (2018)